Nevirapine resistance after single dose prophylaxis.

摘要: Nevirapine (NVP) is a potent non-nucleoside inhibitor of HIV-1 reverse transcriptase. In 1999, the HIVNET 012 trial in Uganda demonstrated that simple regimen NVP prophylaxis can dramatically reduce rate mother-to-child transmission (MTCT). regimen, women received single dose labor, and infants within 72 h birth. The simplicity, efficacy, low cost are attractive for prevention MTCT resource-poor settings. Plans underway to implement this several countries. Single mutations RT cause high level NVP-resistance likely exist most infected patients at levels prior antiretroviral drug exposure. This favors emergence NVP-resistant following has been shown emerge some NVP. Emergence setting more common among with baseline viral loads CD4 cell counts. receiving may also be influenced by subtype. typically fades from detection over time. We review studies examining fading who prophylaxis, discuss potential clinical relevance setting.